search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Anabolic properties of BCKA and BCAA in vivo in older men


- candidate number25317
- NTR NumberNTR6047
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR20-sep-2016
- Secondary IDsMETC 163035 
- Public TitleAnabolic properties of BCKA and BCAA in vivo in older men
- Scientific TitleAnabolic properties of BCKA and BCAA in vivo in older men
- ACRONYM
- hypothesis- We hypothesize that ingestion of BCAA will increase post-prandial plasma amino acid availability, thereby increasing myofibrillar muscle protein synthesis rates above basal values.
- We hypothesize that ingestion of BCKA will increase post-prandial plasma amino acid availability, thereby increasing myofibrillar muscle protein synthesis rates above basal values.
- We hypothesize that BCAA and BCKA is equally or less effective in increasing post-prandial plasma amino acid availability and myofibrillar muscle protein synthesis rates when compared to milk protein.
- Healt Condition(s) or Problem(s) studiedSarcopenia
- Inclusion criteria Healthy males
Age between 65 and 80 y
BMI between 18.5 and 30 kg/m2
- Exclusion criteria Lactose intolerance
Smoking
Diabetes
Diagnosed GI tract diseases
Arthritic conditions
A history of neuromuscular problems
Any medications known to affect protein metabolism (i.e. corticosteroids, non- steroidal anti-inflammatories, or prescription strength acne medications).
Use of anticoagulants
Participation in exercise program
Hypertension, high blood pressure that is above 140/90 mmHg
Females
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-nov-2016
- planned closingdate1-nov-2017
- Target number of participants45
- InterventionsA beverage (300 mL) containing 6 g of BCAA, 6 g of BCKA- or 30 g of milk protein will be consumed.
- Primary outcomePrimary study parameters include post-prandial plasma amino acid availability and myofibrillar muscle protein synthesis rates.
- Secondary outcomeSecondary study parameters include whole-body protein synthesis, breakdown, oxidation, net balance, plasma ammonia, glucose and insulin.
- TimepointsMuscle biopsies will be taken at timepoints: 0h, 2h and 5h after ingestion of the beverage.
- Trial web site
- statusinclusion stopped: follow-up
- CONTACT FOR PUBLIC QUERIES Cas Fuchs
- CONTACT for SCIENTIFIC QUERIES Cas Fuchs
- Sponsor/Initiator Maastricht University
- Funding
(Source(s) of Monetary or Material Support)
Evonik Industries
- Publicationsn/a
- Brief summaryProtein and/or essential amino acids are important for stimulating muscle protein synthesis (MPS) rates and inhibiting muscle protein breakdown. The anabolic properties to protein feeding can be increased by the co-ingestion of free leucine, thereby increasing the amount of dietary protein derived amino acids that are used for de novo muscle protein synthesis. Consequently branched chain amino acid (BCAA) supplementation or fortification can be used to increase MPS. However, supplementing with high amounts of protein and/or BCAA, necessary to stimulate MPS, can be harmful for patients suffering from for example Chronic Kidney Disease (CKD). Supplementation with branched chain keto acids (BCKA) may be of particular relevance in these conditions as these keto analogues do not provide nitrogen (N) and may help to reduce metabolic workload of liver and kidneys. However, it remains to be established whether BCAA and BCKA can be useful in stimulating MPS in vivo in humans.
- Main changes (audit trail)
- RECORD20-sep-2016 - 19-mei-2017


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl